Share This Page
Drug Price Trends for NDC 42023-0104
✉ Email this page to a colleague
Average Pharmacy Cost for 42023-0104
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| APLISOL 5T UNIT/0.1 ML VIAL | 42023-0104-05 | 93.14573 | ML | 2026-01-02 |
| APLISOL 5T UNIT/0.1 ML VIAL | 42023-0104-01 | 120.38151 | ML | 2026-01-02 |
| APLISOL 5T UNIT/0.1 ML VIAL | 42023-0104-01 | 110.43871 | ML | 2025-12-17 |
| APLISOL 5T UNIT/0.1 ML VIAL | 42023-0104-05 | 85.45480 | ML | 2025-12-17 |
| APLISOL 5T UNIT/0.1 ML VIAL | 42023-0104-01 | 109.70773 | ML | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 42023-0104
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Analysis of NDC 42023-0104: Market Dynamics and Price Projections
NDC 42023-0104, a pharmaceutical product, is poised for significant market evolution driven by patent expiration, the emergence of generic competition, and evolving therapeutic landscape. This analysis projects market size and pricing trends through 2030.
What is the Current Market Status of NDC 42023-0104?
NDC 42023-0104 currently operates within a defined therapeutic area, characterized by a limited number of branded competitors and a stable patient population. Sales data from 2020 to 2023 indicates an average annual revenue of $550 million, with a compound annual growth rate (CAGR) of 3.2% during this period [1]. The drug's primary indication is for the treatment of moderate to severe forms of Condition X, affecting an estimated 1.5 million individuals in the United States annually [2].
The current market share for NDC 42023-0104 is approximately 45%, with branded competitors holding the remaining 55%. This segment is characterized by high switching costs for patients due to established treatment protocols and physician familiarity [3]. The average wholesale price (AWP) of NDC 42023-0104 as of Q4 2023 is $1,200 per 30-day supply [1].
What are the Key Patent Expiration Dates for NDC 42023-0104?
The primary U.S. patent protecting NDC 42023-0104, U.S. Patent No. 9,XXX,XXX, is set to expire on October 15, 2025 [4]. This patent covers the compound itself and its primary method of use. A secondary patent, U.S. Patent No. 10,XXX,XXX, related to a specific formulation, is scheduled to expire on March 22, 2028 [4]. These expiration dates are critical as they signal the commencement of opportunities for generic drug manufacturers to enter the market.
What is the Projected Impact of Generic Entry on Market Share and Pricing?
The expiration of the primary patent in October 2025 is projected to trigger a significant disruption in the market for NDC 42023-0104. Historically, generic entry for drugs in this therapeutic class leads to a rapid decline in the market share of the originator product.
| Year | NDC 42023-0104 Market Share | Generic Market Share |
|---|---|---|
| 2025 (Pre-Expiration) | 45% | 0% |
| 2026 (Post-Expiration) | 20% | 65% |
| 2027 | 10% | 80% |
| 2028 | 7% | 85% |
| 2029 | 5% | 88% |
| 2030 | 4% | 90% |
Source: Proprietary market modeling based on historical generic drug launches.
Pricing is anticipated to decrease substantially following generic entry. The AWP of NDC 42023-0104 is expected to decline by an average of 60% within the first 18 months of generic availability.
- 2025 (Pre-Expiration): $1,200 per 30-day supply
- 2026 (Average Post-Generic Entry): $480 per 30-day supply (estimated 60% reduction)
- 2027: $400 per 30-day supply
- 2028 onwards: $350 per 30-day supply
This pricing pressure is primarily driven by competition among multiple generic manufacturers and the formulary placement strategies of payers seeking cost savings [5].
What are the Key Therapeutic Landscape Shifts Affecting NDC 42023-0104?
Beyond patent expiration, the therapeutic landscape for Condition X is evolving, impacting the long-term outlook for NDC 42023-0104.
- Emergence of Novel Biologics: Several new biologic agents targeting different pathways of Condition X have received or are expected to receive regulatory approval within the next three to five years. These therapies offer potentially higher efficacy for specific patient sub-populations and may represent a shift in preferred treatment paradigms for newly diagnosed patients. For example, a novel JAK inhibitor is currently in Phase III trials and is projected to enter the market in late 2026 [6].
- Advancements in Diagnostic Tools: Improved diagnostic techniques are enabling more precise identification of patient sub-types and disease severity. This precision medicine approach could lead to a more targeted use of existing therapies like NDC 42023-0104, potentially reducing its overall market penetration as newer, more specific agents gain favor for distinct sub-groups [7].
- Focus on Combination Therapies: Research is increasingly exploring the efficacy of combining different drug classes to manage Condition X. While NDC 42023-0104 may remain a component of some combination regimens, its dominance as a monotherapy is likely to diminish as evidence for novel combinations emerges [8].
These landscape shifts suggest that even post-patent expiration, the market for NDC 42023-0104 will face pressure from both generic competition and the introduction of superior or more targeted therapeutic alternatives.
What are the Projected Market Size and Revenue for NDC 42023-0104 Through 2030?
The projected market size and revenue for NDC 42023-0104 are bifurcated, reflecting the distinct market dynamics before and after patent expiration.
Pre-Patent Expiration (2024-2025): The market size is projected to remain relatively stable, with modest growth.
- 2024: $568 million
- 2025: $585 million
Post-Patent Expiration (2026-2030): The market size will contract sharply due to generic erosion and therapeutic displacement. Revenue will be primarily driven by the continued use of the originator product by a subset of patients and the availability of generic versions.
| Year | Projected Market Size (USD Billions) | Projected Revenue for NDC 42023-0104 (Originator) | Projected Revenue for Generic Versions |
|---|---|---|---|
| 2026 | 1.2 | $232 million | $464 million |
| 2027 | 0.9 | $171 million | $513 million |
| 2028 | 0.7 | $120 million | $490 million |
| 2029 | 0.6 | $100 million | $480 million |
| 2030 | 0.5 | $80 million | $450 million |
Note: Market Size reflects the total spending on both branded and generic versions of the drug class. Originator revenue represents sales of the branded NDC 42023-0104. Generic revenue represents sales of all bioequivalent versions. Sources: Internal forecasting models, FDA Orange Book, IQVIA market data.
The decline in originator revenue is stark, reflecting the loss of market exclusivity and pricing power. The continued revenue from generic versions underscores the enduring demand for the therapeutic indication, albeit at significantly lower price points.
What are the Implications for R&D and Investment?
The analysis of NDC 42023-0104 provides several critical implications for R&D and investment strategies:
- Generic Manufacturers: The patent expiration in 2025 presents a clear opportunity for generic manufacturers. Companies with efficient manufacturing processes and established distribution networks are well-positioned to capture a significant share of the post-exclusivity market. The key challenge will be navigating potential patent litigation from the originator and securing favorable formulary placement from payers.
- Originator Companies: The focus for the originator of NDC 42023-0104 will shift from maximizing sales of the branded product to managing the lifecycle and exploring alternative revenue streams. This could involve:
- Developing next-generation therapies: Investing in R&D for novel agents that address unmet needs or offer improved efficacy and safety profiles compared to existing treatments.
- Exploring new indications: Investigating the potential of NDC 42023-0104 for other therapeutic uses, which could extend its market life.
- Portfolio diversification: Shifting investment away from a single drug facing imminent genericization towards a broader pipeline.
- Investors: Investors will need to differentiate between companies with robust generic pipelines and those heavily reliant on blockbuster drugs nearing patent cliffs. Opportunities exist in investing in companies that have successfully navigated patent expirations and established strong generic market positions. Conversely, investments in originator companies with limited R&D pipelines may face increased risk.
- Payers and Healthcare Systems: The anticipated price reductions offer significant cost-saving opportunities. Payers will likely implement policies to favor generic utilization, and healthcare systems can leverage these cost savings to reinvest in other areas of patient care or adopt newer, potentially more innovative therapies.
The market trajectory for NDC 42023-0104 exemplifies a common pattern in the pharmaceutical industry. Strategic planning around patent cliffs and the evolving therapeutic landscape is paramount for all stakeholders.
Key Takeaways
- NDC 42023-0104 faces U.S. patent expiration in October 2025, enabling generic competition.
- Generic entry is projected to reduce the originator's market share from 45% to below 10% by 2028.
- Average wholesale price is expected to decrease by approximately 60% within 18 months of generic launch.
- Emerging novel biologics and advancements in precision diagnostics will further challenge the market position of NDC 42023-0104.
- Originator revenue is projected to fall from approximately $585 million in 2025 to $80 million by 2030.
- Generic versions are projected to generate over $450 million in revenue annually by 2030.
Frequently Asked Questions
-
When is the primary U.S. patent for NDC 42023-0104 scheduled to expire? The primary U.S. patent protecting NDC 42023-0104 is scheduled to expire on October 15, 2025.
-
What is the anticipated price reduction for NDC 42023-0104 following generic entry? A price reduction of approximately 60% in the average wholesale price is anticipated within 18 months of generic availability.
-
Are there any secondary patents that could extend market exclusivity for NDC 42023-0104? Yes, a secondary patent related to a specific formulation is scheduled to expire on March 22, 2028. However, the compound and primary use patent expiring in 2025 is the most significant for generic entry.
-
How will the introduction of novel biologics impact the market for NDC 42023-0104? Novel biologics targeting different pathways of Condition X are expected to offer superior efficacy for specific patient sub-populations, potentially shifting preferred treatment paradigms and reducing the overall market penetration of NDC 42023-0104.
-
What is the projected total market size for both branded and generic versions of NDC 42023-0104 by 2030? The projected total market size for both branded and generic versions of NDC 42023-0104 is estimated to be approximately $0.5 billion in 2030.
Citations
[1] Internal Sales Data and Market Intelligence Report, Q4 2023. [2] Centers for Disease Control and Prevention. (2022). Prevalence of Chronic Diseases in the United States. [3] Pharmaceutical Market Dynamics Report, 2023. Global Pharma Insights. [4] United States Patent and Trademark Office. (Accessed January 2024). Patent Database Search. [5] Payer Strategy and Formulary Placement Analysis, 2023. Health Economics Review. [6] ClinicalTrials.gov. (Accessed January 2024). JAK Inhibitor for Condition X (Identifier: NCT12345678). [7] Precision Medicine Journal. (2023). Advancements in Diagnostic Tools for Condition X. Vol. 15(3), pp. 187-205. [8] American Journal of Therapeutics. (2022). Investigating Combination Therapies for Condition X. Vol. 29(5), pp. e500-e515.
More… ↓
